All In Biotech

Drug Trial Radar · NCT04083781

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

134

Actual

Start

Oct 21, 2019

Primary completion

Dec 27, 2021

Study completion Feb 21, 2027

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleeds (on-demand) will be placed in one of two groups. In one group, participants will get study medicine from the start of the study. In the other group, participants will continue with their normal medicine and get study medicine after 6 months. Which treatment the participant gets is decided by chance. Participants who usually take medicine to prevent bleeds (prophylaxis treatment) or who are already being treated with concizumab (study medicine) will receive the study medicine from the start of the study. Participants will get 1 injection with the study medicine every day under the skin. This participants will have to do themselves and can be done at home. The study doctor will hand out the medicine in the form of a pen-injector. The pen-injector will contain the study medicine. The study will last for about seven years. The length of time the participants will be in the study depends on when they agreed to take part or when the medicine is available for purchase in their country (31 December 2026 at the latest). The time between visits will be approximately 4 weeks for the first 6 to 12 months, depending on the group participants are in and approximately 8 weeks for the rest of the study. Participants will be asked to record information into an electronic diary during the study and may also be asked to wear an activity tracker.

Conditions

  • Haemophilia A With Inhibitors
  • Haemophilia B With Inhibitors

Interventions

  • ConcizumabDrug

    Concizumab will be administered daily subcutaneously (s.c., under the skin). When patients are randomised to concizumab prophylaxis they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week 0: arm 2, 3 \& 4) or visit 9a (week 24: arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (week 6: arm 2, 3 \& 4) or 9a.3 (week 30: arm 1) and will be based on the concizumab exposure level measured at the previous visit 4a (week 4) or 9a.2 (week 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual bypassing product until visit 9a (week 24: end of main part for arm 1).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Treated Spontaneous and Traumatic Bleeding EpisodesTime frame: On demand (arm 1): From week 0 up until start of concizumab treatment (at least 24 weeks) Concizumab (arm 2): From week 0 up until the primary analysis cut-off (at least 32 weeks)

Locations

99 sites in 29 countries. Site status is shown where the registry gives one.

  • Center for Inherited Blood Dis

    Orange, California

  • Children's Healthcare Atlanta

    Atlanta, Georgia

  • Indiana Hemophilia-Thromb Ctr

    Indianapolis, Indiana

  • Washington University School of Medicine_St. Louis

    St Louis, Missouri

  • St. Jude Affiliate Clinic at Novant Health Hemby Children's

    Charlotte, North Carolina

  • TriStar Medical Group Children's Specialist

    Nashville, Tennessee

  • University of Texas San Antonio

    San Antonio, Texas

  • Haematology and Blood Bank Department

    Algiers, Algeria

  • CHU Constantine BEN BADIS/ Hematology department

    Constantine, Algeria

  • The Alfred

    Melbourne, Victoria, Australia

  • The Royal Children's Hospital

    Parkville, Victoria, Australia

  • Fiona Stanley Hospital - Haemophilia and Haemostasis Centre

    Murdoch, Western Australia, Australia

  • Klin. Abt. f. Hämatologie und Hämostaseologie, AKH Wien

    Vienna, Austria

  • UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology

    Sofia, Bulgaria

  • Hamltn Hth Sci/McMstr Child Hosp

    Hamilton, Ontario, Canada

  • KBC Zagreb, Rebro, Hemofilija centar

    Zagreb, Croatia

  • KBC Zagreb_Hematology

    Zagreb, Croatia

  • KBC Zagreb, Zavod za pedijatrijsku hematologiju

    Zagreb, Croatia

  • Ustav Hematologie a krevni tranfuze

    Prague, Czechia

  • Fakultni Nemocnice Motol A Homolka

    Prague, Czechia

  • Skejby Blodsygdomme, blødercentret

    Aarhus N, Denmark

  • Hospices Civils de Lyon- Hopital Louis Pradel

    Bron, France

  • Centre Hospitalier de Clermont-Ferrand-Hopital Estaing

    Clermont-Ferrand, France

  • Ap-Hp-Hopital de Bicetre

    Le Kremlin-Bicêtre, France

  • Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou

    Rennes, France

  • All India Institute of Medical Sciences_New Dehli

    New Delhi, India

  • St. John's Medical college and Hospital

    Bangalore, Karnataka, India

  • Sahyadri Speciality Hospital

    Pune, Maharashtra, India

  • Sahyadri Super Speciality Hospital

    Pune, Maharashtra, India

  • All India Institute of Medical Sciences_New Dehli

    New Dehli, New Delhi, India

  • CMCV

    Ranipet, Tamil Nadu, India

  • CMCV

    Ranipet, Tamil Nadu, India

  • Istituto Oncologico Veneto - Oncoematologia IOV

    Castelfranco Veneto, Italy

  • Oncoematologia IOV

    Castelfranco Veneto, Italy

  • Istituto di Medicina Int. A. Bianchi Bonomi Univ. Milano

    Milan, Italy

  • Azienda OU "S.Maria della Misericordia"

    Udine, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Donna Bambino Borgo Trento - U.O.C. Oncoematologia Pediatrica

    Verona, Italy

  • Ospedale Donna Bambino U.O.C. Oncoematologia Pediatrica

    Verona, Italy

  • Dipartimento di Ematologia Univ. Firenze

    Florence, FI, Italy

  • Nagoya University Hospital_Blood Transfusion

    Aichi, Japan

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.